

P1891

Abstract (poster session)

Comparative activity of various antibiotics alone and in combination against high inocula methicillin-resistant *Staphylococcus aureus* with reduced susceptibilities to vancomycin

T.P Lim*, W. Lee, S. Sasikala, N. Rafida, T.Y Tan, L.Y Hsu, J. Teo, A.L Kwa (Singapore, SG)

Background: Methicillin-Resistant *Staphylococcus aureus* (MRSA) is endemic worldwide, with increasing vancomycin (V) heteroresistance. Many new antibiotics (abx) developed are active against MRSA but the optimal chemotherapy is not well defined in endocarditis & osteomyelitis (high inocula infections). We aim to examine the utility of various abx alone & in combination (combi) at high inocula for potential clinical use against a variety of well characterized MRSA with vancomycin heteroresistance. Methods: 10 well-known MRSA clones [ST239 V-intermediate, UK-EMRSA-15, ST30 community-associated (CA) & ST8 USA300 CA) were selected for the study. Minimum inhibitory concentrations (MIC) were determined according to reference broth-dilution methods. Time-kill studies (TKS) were performed with 8 log CFU/ml at baseline using maximum achievable, clinical, unbound concentrations (mg/L) of linezolid (L) (19), daptomycin (D) (5), rifampicin (R) (2), tigecycline (T) (2) & V (12) alone & in combi against the test strains. Bactericidal (≥ 3 log CFU/ml drop from baseline inocula) activity & synergism (≥ 2 log CFU/ml drop from most active abx) were evaluated at 24h. Results: The test strains had T MICs of 0.06 – ≥ 8 mg/L, R MICs of ≤ 0.06 mg/L, V MICs of 1 – 4 mg/L, D MICs of 0.5 – ≥ 16 mg/L & L MICs of 0.06– ≥ 16 mg/L. In single TKS, there were at least 1 abx alone that exhibited bactericidal activity in 4/10 strains; D,L & V was bactericidal against strain 1(4.29 log), 2(4.85 log) & 7(4.48 log) respectively, while T & R individually was bactericidal against strain 6(4.95 log & 4.74 log respectively). In combi TKS for these 4 strains, only L+R was bactericidal against strain 1(5.00 log) & D+T was bactericidal against strain 2(3.51 log) at 24h. In 6/10 strains (3, 4, 5, 8, 9, 10) where no abx alone exhibited bactericidal activity, the combi TKS showed that only D+T was bactericidal against strain 9(4.52 log), D+T & T+R were bactericidal against strain 8(4.42 log & 4.79 log respectively), D+R & D+V were synergistic against strain 3 (5.90 log for both combi). Conclusions: Combi therapy may be useful against MRSA infections with reduced susceptibilities to V based on the encouraging in vitro activity. However, 2-drug abx combi may not be sufficient to totally eradicate the infection. Our approach may be used to identify abx combi that can be used for long-term adjuvant antibiotic therapy in clinical situations like osteomyelitis. Further research is warranted.